Low-Dose Naltrexone: An Off-Label Approach to Immune Modulation and Chronic Pain

This article is for informational purposes only and does not constitute medical advice. Superpower Health facilitates access to compounded low-dose naltrexone through licensed providers and compounding pharmacy partners. Low-dose naltrexone is not FDA-approved at low doses and is used off-label. Always consult a qualified healthcare provider before starting any prescription compound.

The same drug used for decades at high doses to manage opioid addiction produces a pharmacologically distinct set of effects at a fraction of that dose. At 50 mg, naltrexone occupies opioid receptors continuously, blocking endogenous opioid signaling. At 1.5 to 4.5 mg — taken nightly — the dynamics reverse. A brief, transient receptor blockade provokes a rebound in endogenous opioid production and simultaneously modulates the glial immune cells that drive neuroinflammation. The mechanism is different, the applications are different, and the evidence, though still developing, is distinct enough to warrant careful attention.

Low-dose naltrexone (LDN) is not an FDA-approved formulation. Superpower Health facilitates access to compounded LDN through its licensed provider network. Here is what the research currently supports, what it does not, and which biomarkers providers typically assess before prescribing it.

Key Takeaways

• Regulatory Status: Naltrexone is FDA-approved at 50 mg for opioid use disorder and alcohol use disorder. LDN (1.5–4.5 mg) is off-label only. No separate FDA approval exists for low-dose formulations. Any off-label use is the independent clinical judgment of the prescribing physician.
• Research Stage: Early-to-mid stage clinical evidence; studied in fibromyalgia, Crohn's disease, multiple sclerosis, and chronic pain; larger RCTs are ongoing or needed
• Availability: Prescription only; compounded formulations only — no brand-name LDN exists. Available through Superpower's licensed provider network and licensed 503A compounding pharmacy partners.
• Prescribing information: View naltrexone 50 mg prescribing information (DailyMed) — LDN is off-label; no separate DailyMed label exists for low-dose formulations
• How it works: Transient opioid receptor blockade at low doses upregulates endogenous opioids and modulates glial TLR4 signaling, reducing neuroinflammation.
• What the research shows: Early evidence suggests potential benefit in fibromyalgia, Crohn's disease, and multiple sclerosis, but results are mixed and larger trials are needed.

What Is Low-Dose Naltrexone?

Naltrexone is an opioid antagonist, originally approved by the FDA in 1984 at 50 mg for opioid use disorder and subsequently for alcohol use disorder. The brand name for the standard-dose formulation is Vivitrol (extended-release injectable) and ReVia (oral tablet). Low-dose naltrexone refers specifically to compounded oral formulations at 1.5 to 4.5 mg taken nightly. No pharmaceutical manufacturer produces an approved low-dose naltrexone product. LDN must be obtained from licensed 503A compounding pharmacies with a prescription. The clinical interest in LDN emerged from observations by Bernard Bihari in the 1980s and has since generated a growing body of exploratory research across autoimmune and chronic pain conditions.

Important distinction: The weight loss compound Contrave is naltrexone 32 mg combined with bupropion 360 mg daily — a pharmacologically and clinically distinct product from LDN monotherapy. The PCOS literature on naltrexone largely concerns standard-dose naltrexone-bupropion combination therapy, not LDN. These bodies of evidence do not apply to LDN at 1.5 to 4.5 mg.

How Low-Dose Naltrexone Works in the Body

Transient Opioid Receptor Blockade and the OGF Rebound

At standard doses (50 mg), naltrexone produces sustained opioid receptor antagonism lasting 24 to 72 hours. At low doses (1.5–4.5 mg) taken at night, receptor blockade lasts only 4 to 6 hours before the drug is cleared. This brief blockade is proposed to disrupt the negative feedback loop governing opioid growth factor (OGF) — specifically met-enkephalin — and its receptor OGFr. When the receptor is transiently blocked, the body upregulates endogenous OGF production in a rebound response. When the drug clears and receptors become available again, elevated OGF levels provide a net increase in endogenous opioid activity. A 2018 comprehensive review by Toljan and Vrooman in Medical Sciences identified three distinct mechanistic pathways for LDN at 1 to 5 mg daily — transient opioid receptor blockade with rebound beta-endorphin upregulation, TLR4 antagonism on microglia and macrophages, and OGFr-mediated cell proliferation regulation — and cited a fibromyalgia crossover trial in which overall symptom reduction was 32.5% on LDN versus 2.3% on placebo, with 57% of participants classified as responders. The review describes this rebound mechanism as central to LDN's proposed anti-proliferative and immune-regulatory effects across conditions including fibromyalgia, Crohn's disease, multiple sclerosis, and complex regional pain syndrome. This mechanism is pharmacologically distinct from what happens at standard naltrexone doses.

TLR4 Modulation and Glial Neuroinflammation

Naltrexone has a secondary mechanism of action independent of opioid receptor binding: it inhibits Toll-like receptor 4 (TLR4) signaling on microglia and astrocytes, the central nervous system's primary immune surveillance cells. TLR4 is a pattern recognition receptor that activates neuroinflammatory cascades when stimulated by bacterial lipopolysaccharides or endogenous damage signals. Microglial TLR4 activation drives the release of pro-inflammatory cytokines — including TNF-alpha, IL-1 beta, and IL-6 — that contribute to central sensitization and chronic pain amplification. A 2014 review by Younger and Parkitny in Clinical Rheumatology identified TLR4 modulation on microglial cells as a primary candidate mechanism for LDN's analgesic effects in conditions like fibromyalgia. This pathway operates independently of the opioid receptor, meaning its effects persist throughout the dosing period rather than only during receptor blockade.

Immune Modulation Beyond the CNS

LDN's effects on innate immune signaling extend beyond the central nervous system. TLR4 receptors are expressed in peripheral immune cells, intestinal epithelium, and inflammatory tissue. In inflammatory bowel disease, this peripheral TLR4 modulation is proposed to reduce mucosal inflammation and promote intestinal healing. A 2018 single-arm prospective cohort study by Lie and Giessen in the Journal of Translational Medicine — conducted without a placebo comparator — followed 47 therapy-refractory IBD patients prescribed 4.5 mg naltrexone daily for 12 weeks and found that 74.5% achieved clinical improvement and 25.5% achieved sustained remission, with endoscopic inflammation scored on a 0-to-3 severity scale showing that patients in clinical remission had significantly greater endoscopic improvement than non-remitters (median change −1.5 versus +1.0, p = 0.005), alongside objective improvements in wound healing and reduced mucosal endoplasmic reticulum stress. Systemic OGF upregulation also appears to modulate T-cell and NK-cell activity, with implications for autoimmune dysregulation, though clinical translation of these effects remains under active investigation.

The Night-Dosing Requirement

LDN is typically prescribed for nightly administration, usually at bedtime, for a pharmacokinetically specific reason. Endogenous opioid production is thought to coincide with an early morning surge between 2 and 4 a.m. Taking LDN 2 to 3 hours before this peak allows the transient blockade to interrupt the period of highest OGF receptor availability, maximizing the rebound response. This timing strategy is based on mechanistic reasoning supported by the Toljan and Vrooman review; formal dose-timing RCTs are limited. Providers determine appropriate timing and formulation based on individual clinical context. Sleep disturbance — vivid dreams, insomnia — is the most commonly reported side effect associated with nighttime dosing and typically resolves within the first 2 to 4 weeks.

What the Research Shows About Effectiveness

Fibromyalgia: Mixed Evidence Across Recent Meta-Analyses

Fibromyalgia is the most studied condition in the LDN literature, and the evidence base is genuinely mixed. Two significant meta-analyses reached different conclusions within a 12-month window, and both should be considered. A 2024 meta-analysis by Vatvani and Patel in the Korean Journal of Pain pooled 4 RCTs with 214 fibromyalgia patients receiving LDN at 1.5 to 4.5 mg daily versus placebo and found a significant reduction in pain scores (MD −0.86, 95% CI −1.20 to −0.51, p < 0.001), with trial sequential analysis confirming the result crossed monitoring boundaries for a beneficial effect. A separate 2025 meta-analysis by Ologunowa and Otoo in the Journal of Pain and Palliative Care Pharmacotherapy pooled 8 RCTs and reached a more cautious conclusion: while LDN reduced pain by SMD −1.03 (95% CI −1.25 to −0.80) compared to baseline, the between-group comparison against placebo was not statistically significant (SMD −0.50, 95% CI −1.19 to 0.19), suggesting that LDN may not provide clinically significant benefit over placebo when the full evidence base is evaluated. A 2023 systematic review by Partridge and Quadt in Heliyon also found low RCT effectiveness despite favorable observational signals. The divergence across these analyses reflects differences in included studies, outcome definitions, and statistical thresholds for clinical significance. The honest summary: LDN shows a consistent biological signal in fibromyalgia, but whether that signal translates to clinically meaningful symptom relief is not yet established with confidence.

Multiple Sclerosis

Multiple sclerosis is the third well-studied application for LDN. A 2010 pilot RCT by Cree and Kornyeyeva published in Annals of Neurology enrolled 80 patients with relapsing-remitting MS (60 completed) and found that LDN at 4.5 mg nightly for 8 weeks improved the SF-36 Mental Component Summary score by 3.3 points versus placebo (p = 0.04) and the Mental Health Inventory by 6 points (p < 0.01). A separate 2010 RCT by Sharafaddinzadeh and Moghtaderi in Multiple Sclerosis Journal enrolled 96 patients with relapsing-remitting or secondary progressive MS in a 17-week placebo-controlled crossover trial of 4.5 mg naltrexone nightly and found that LDN was relatively safe but did not produce significant improvements on MSQoL-54 physical or mental health composite scores versus placebo, underscoring the mixed signal across trials. A 2016 retrospective study by Ludwig and Turel at Penn State reviewed 23 relapsing-remitting MS patients prescribed 4.5 mg LDN over a mean follow-up of 3 years (within a 10-year data collection period) and found no significant differences in clinical laboratory values, timed walking, or MRI changes, with half of patients maintaining stable disease status throughout follow-up. LDN is not an approved disease-modifying therapy for MS and should not replace established DMTs. These findings pertain to symptom management and quality of life, not disease modification.

Chronic Pain and Cross-Indication Findings

A 2025 meta-analysis by Hegde and colleagues in Current Pain and Headache Reports pooled 7 RCTs of LDN (1.5 to 4.5 mg daily) across chronic pain syndromes and found no significant overall difference versus control groups (d = −0.11, 95% CI −0.96 to 0.74, p = 0.31), but the fibromyalgia-specific subgroup did show a significant benefit over placebo (d = −0.34, 95% CI −0.62 to −0.06, p = 0.02), while LDN was comparable to active comparators across broader chronic pain conditions. This cross-indication analysis suggests a coherent biological signal across conditions characterized by central sensitization and neuroinflammation, consistent with the TLR4 mechanism, though it does not substitute for indication-specific RCTs.

Side Effects and What to Expect

LDN has a favorable tolerability profile relative to both standard-dose naltrexone and many medications used for the same conditions. Most adverse effects are mild and transient, particularly in the initial weeks of use.

Common side effects:

• Sleep disturbances: vivid or unusual dreams, insomnia (most commonly reported; typically resolves within 2 to 4 weeks; may improve with dose reduction or switching to morning dosing in consultation with a provider)
• Nausea: particularly in the first 1 to 2 weeks; usually transient
• Headache: mild; typically resolves with continued use
• Fatigue or drowsiness at initiation

Less common but clinically important:

• Hepatotoxicity: elevated liver enzymes have been reported with standard-dose naltrexone, particularly at doses above 50 mg/day. A 2006 controlled study by Yen and colleagues in Alcohol monitored 74 alcoholic patients receiving 50 mg naltrexone daily for 12 weeks versus placebo and found statistically significant decreases in ALT and AST levels over the treatment period, with no hepatotoxic elevations except in one subject, though liver enzyme monitoring remains standard clinical practice given earlier case reports at supratherapeutic doses. At LDN doses, hepatotoxicity is not a prominent concern.
• Opioid withdrawal precipitation: if a patient has any residual opioid activity (including from pain medications taken in the preceding days), even LDN can precipitate acute withdrawal. Providers confirm opioid-free status before initiating. A minimum washout period is required.
• Hypersensitivity reactions: rare

A 2018 literature review by Patten and Schultz in Pharmacotherapy characterizing LDN tolerability across MS, fibromyalgia, and Crohn's disease found the safety profile to be well-characterized across these conditions. No severe adverse events were reported in the majority of studies reviewed. However, the review also called for larger controlled trials to establish the evidence base more definitively.

Who Is LDN Typically Prescribed For?

Autoimmune and Inflammatory Conditions

LDN is most commonly considered for patients with autoimmune conditions, chronic inflammatory disease, or chronic pain syndromes where conventional management has been inadequate or poorly tolerated. Fibromyalgia, inflammatory bowel disease (particularly Crohn's disease), multiple sclerosis, and other conditions characterized by central sensitization or dysregulated innate immunity are the primary clinical contexts. The evidence base includes a 2024 meta-analysis by Vatvani and Patel reporting a biological signal in fibromyalgia, a 2014 Cochrane review by Segal and MacDonald identifying possible benefits in active Crohn's disease, and a 2010 pilot RCT by Cree and Kornyeyeva showing improved quality of life in relapsing-remitting MS. LDN is not FDA-approved for any of these indications. Any prescription for LDN represents off-label use based on the independent clinical judgment of the prescribing physician. The safety and efficacy of LDN for these uses have not been established through adequate and well-controlled clinical trials reviewed by the FDA. Providers evaluate individual risk-benefit profiles before prescribing.

Chronic Pain

The TLR4-mediated anti-neuroinflammatory mechanism — identified by Younger and Parkitny (2014) as a primary candidate pathway for LDN's analgesic effects — makes LDN a biologically coherent candidate for chronic pain conditions associated with central sensitization, including fibromyalgia, complex regional pain syndrome, and neuropathic pain. A 2025 cross-indication meta-analysis by Hegde and colleagues found that LDN showed pain reduction benefits in fibromyalgia-specific analyses and was comparable to active controls across chronic pain syndromes. Providers typically consider LDN in this context when conventional analgesic options have been exhausted or when long-term opioid use is clinically undesirable. LDN does not interact with standard opioid pain management in an additive way; rather, it requires careful coordination with any opioid prescription due to antagonist effects.

Who Should Not Take LDN

A licensed provider will evaluate individual risk factors before prescribing. The following are recognized contraindications or conditions requiring significant clinical caution:

• Current opioid use or dependence: LDN can precipitate acute opioid withdrawal even at low doses. Based on standard-dose naltrexone detox protocols, patients must be fully opioid-free for a minimum of 3 to 5 days (or longer, depending on the opioid and formulation) before initiating LDN. Note that this timeline derives from standard-dose naltrexone data, not LDN-specific studies. Providers confirm opioid-free status before prescribing.
• Concurrent use of opioid-containing medications: includes opioid analgesics, opioid antidiarrheal agents (loperamide at therapeutic doses), and opioid-containing cough suppressants
• Severe hepatic impairment: naltrexone undergoes hepatic metabolism. While a 2006 controlled study by Yen and colleagues found no hepatotoxic effects in 74 patients receiving standard-dose naltrexone over 12 weeks, liver function testing is required before initiation given earlier case reports at supratherapeutic doses.
• Pregnancy and breastfeeding: safety has not been established in these populations
• Known hypersensitivity to naltrexone or any component of the compounded formulation
• Planned surgical procedures requiring opioid analgesia: providers coordinate timing of LDN discontinuation with surgical teams to ensure adequate opioid pain management is possible post-operatively

This is not an exhaustive list. A licensed provider will evaluate the full clinical picture before prescribing LDN.

What to Test Before Starting LDN

Because LDN acts primarily through immune and neuroimmune pathways, and because standard-dose naltrexone carries hepatotoxicity risk at higher doses, pre-treatment testing establishes both safety and baseline immune and inflammatory status. The following markers are clinically relevant before starting LDN:

• Liver function tests (ALT, AST, GGT, alkaline phosphatase, bilirubin): Standard-dose naltrexone carries a dose-dependent risk of hepatotoxicity. While this risk is substantially lower at LDN doses, hepatic function testing is standard clinical practice before initiation. A full liver function panel through liver health biomarker testing establishes baseline and identifies contraindications.
• hs-CRP (high-sensitivity C-reactive protein): A sensitive systemic marker of inflammation. LDN's proposed mechanism centers on reducing neuroinflammation and systemic inflammatory signaling. Baseline hs-CRP establishes the inflammatory context and provides a reference point for tracking response over time, particularly in autoimmune or chronic pain presentations.
• CBC (complete blood count) with differential: Baseline white blood cell count and differential provide immune system context before initiating a drug that modulates innate immune signaling. Changes in WBC patterns during therapy may be relevant in autoimmune conditions. Relevant context through the immune system biomarker guide.
• Comprehensive metabolic panel (CMP): Covers liver and kidney function markers. Renal function is relevant to drug clearance; hepatic function is directly tied to safety screening for naltrexone at any dose. Also establishes baseline metabolic status.
• Thyroid function (TSH, Free T3, Free T4): Thyroid autoimmunity is one of the most common autoimmune conditions, and LDN has been discussed in clinical communities focused on Hashimoto's thyroiditis and other autoimmune thyroid disease. Establishing thyroid status at baseline differentiates thyroid-mediated symptoms from other drivers before starting any immune-modulating compound.
• Erythrocyte sedimentation rate (ESR): Alongside hs-CRP, ESR provides a second systemic inflammatory reference point. Both markers together characterize the baseline inflammatory burden across different acute-phase pathways.
• Opioid screening: Not a blood test, but clinical confirmation of opioid-free status is mandatory before LDN initiation. Providers may use urine toxicology to confirm opioid absence.

What Your Bloodwork May Show While on LDN

Providers monitoring patients on LDN typically track inflammatory markers to assess biological response. ESR and hs-CRP are commonly followed markers: a 2009 pilot study by Younger and Mackey in Pain Medicine enrolled 10 women with fibromyalgia taking 4.5 mg LDN daily for 8 weeks and found that baseline ESR predicted over 80% of the variance in drug response (R² ≈ 0.80), with individuals with higher sedimentation rates showing the greatest symptom reduction, and a 2017 single-blind crossover study by Parkitny and Younger in Biomedicines enrolled 8 women with fibromyalgia taking 4.5 mg LDN daily and found reduced plasma concentrations of IL-1β, IL-6, IL-12p70, TNF-α, and 13 other cytokines after eight weeks, alongside a 15% reduction in pain and 18% reduction in overall symptoms versus baseline. Serial measurements over months may show directional trends. CBC differential, particularly the neutrophil-to-lymphocyte ratio and other immune indices, can provide additional context in autoimmune presentations. Liver enzymes should be rechecked periodically to confirm ongoing hepatic safety, particularly in patients with any pre-existing hepatic vulnerability — a 2019 meta-analysis by Bolton and colleagues in BMC Medicine across 89 RCTs with 11,194 patients found no increased risk of serious adverse events for oral naltrexone versus placebo (RR 0.84, 95% CI 0.66–1.06) — noting that these trials predominantly used standard-dose naltrexone (50 mg), not LDN specifically — and no hepatotoxicity has been documented at LDN doses, but periodic monitoring remains standard clinical practice. For patients using LDN for fibromyalgia or chronic pain, symptom-based outcome measures (like patient-reported pain scores) are often as important as any biomarker change, since LDN's primary mechanism — TLR4 antagonism on microglial cells in the CNS, as described by Younger, Parkitny, and McLain in a 2014 review in Clinical Rheumatology — may not always produce obvious systemic blood marker shifts.

That framework — establish objective baselines, then track what actually changes — is central to Superpower's approach to preventive health. For a compound like LDN, where the evidence is real but still maturing, objective biomarker data before and during use is what makes the clinical story interpretable rather than anecdotal.

Frequently Asked Questions

What is the difference between low-dose and standard naltrexone?

Standard naltrexone (50 mg) produces sustained, continuous opioid receptor blockade over 24 to 72 hours. This is the mechanism underlying its FDA-approved use in opioid and alcohol use disorder. Low-dose naltrexone (1.5 to 4.5 mg) produces a brief, transient receptor blockade lasting 4 to 6 hours, which is proposed to trigger a rebound in endogenous opioid production and modulate glial TLR4 signaling. The two dose ranges have pharmacologically distinct mechanisms and are used for entirely different clinical purposes.

What should I avoid when taking low-dose naltrexone?

Any opioid-containing medication must be avoided during LDN use, as LDN can block opioid receptors and precipitate withdrawal or significantly blunt the effectiveness of opioid medications. This includes prescription opioid analgesics, some cough and cold preparations, and loperamide at higher doses. Individuals planning surgical procedures requiring opioid analgesia should coordinate with their provider about temporarily stopping LDN. Grapefruit is not a known interaction, but providers review the full medication list for any compounds metabolized through overlapping pathways.

Does LDN help with autoimmune conditions?

LDN has been studied in Crohn's disease, multiple sclerosis, fibromyalgia, and other inflammatory and autoimmune conditions. The evidence suggests a consistent biological signal based on its TLR4-modulating and endogenous opioid-upregulating mechanisms. Clinical outcomes in controlled trials have been mixed, with some conditions showing stronger evidence than others. LDN is not FDA-approved for any autoimmune indication. The decision to use LDN for an autoimmune condition is the independent clinical judgment of the prescribing physician, made after evaluating the individual patient's diagnosis, other treatments, and overall risk-benefit profile.

Is LDN available as a brand-name medication?

No. There is no FDA-approved brand-name low-dose naltrexone product. LDN must be obtained from a licensed 503A compounding pharmacy with a valid prescription. The standard-dose drug is available as branded products (ReVia 50 mg oral tablets, Vivitrol injectable), but neither of these is used for LDN therapy. Superpower facilitates access to compounded LDN through its licensed provider network and compounding pharmacy partners.

How long does it take for LDN to work?

Most clinical observations suggest an initial response period of 4 to 12 weeks before meaningful symptom changes are apparent. Providers typically begin at a lower dose (1.5 mg) and titrate upward to minimize sleep-related side effects in the first weeks. Inflammatory biomarker changes, if they occur, may lag behind symptom changes. The full assessment of benefit is typically made at 3 to 6 months.

Does LDN cause weight loss?

No. LDN monotherapy at 1.5 to 4.5 mg has not been demonstrated to cause weight loss in clinical trials. The weight loss evidence for naltrexone concerns Contrave — a fixed-dose combination of naltrexone 32 mg and bupropion 360 mg daily — which is an entirely different product, dose, and mechanism. Contrave is FDA-approved for chronic weight management. LDN monotherapy is not Contrave, and the two should not be conflated.

What blood tests should I get before starting LDN?

Key pre-treatment markers include liver function tests (ALT, AST, GGT, alkaline phosphatase, bilirubin) to establish hepatic safety, hs-CRP and ESR as inflammatory baselines, CBC with differential for immune context, a comprehensive metabolic panel, and thyroid function if autoimmune thyroid disease is relevant to the clinical picture. Opioid-free status must also be confirmed by a provider before initiating. A provider determines the appropriate scope of testing based on the specific indication and individual clinical context.

IMPORTANT SAFETY INFORMATION

Naltrexone is an FDA-approved prescription medication approved at 50mg for opioid use disorder and alcohol use disorder. Low-dose naltrexone (LDN) refers to naltrexone prescribed at doses of 1.5-4.5mg, substantially lower than approved dosing. LDN is not FDA-approved. Off-label prescribing is a legal and common medical practice, but the uses described on this page have not been reviewed or approved by the FDA. Compounded LDN is prepared by a licensed pharmacy based on your provider's prescription. Superpower does not prescribe or dispense medications.

Contraindicated: patients currently using opioid medications or in acute opioid withdrawal. Concurrent opioid use with naltrexone can precipitate severe withdrawal.

Warnings: liver function should be monitored. Naltrexone carries a boxed warning regarding hepatotoxicity at higher doses (50mg+); clinical significance at low doses is not established but liver monitoring is standard practice.

Common side effects: sleep disturbances (vivid dreams, insomnia), nausea, headache, mood changes.